PR Newswire Clinical TrialsOriginal article
PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
Phase 1positivePMB-CT01Positive
AI Analysis
Summary
PeproMene Bio announced Phase 1 trial results for PMB-CT01, a BAFF-R-targeted therapy, published in The Lancet demonstrating deep and durable complete remissions in relapsed/refractory B-cell lymphoma patients, including those who previously failed CD19-CAR-T therapy.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Deep and durable complete remissions in relapsed/refractory B-cell lymphoma, including in patients who previously failed CD19-CAR-T therapy
Importance:6/10
Sentiment:
0.85
Phase 1 dataOncologyCAR-TLymphomaPublicationClinical Trial
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 10:01 AM